GlassScriptPhysician profile
Franziska Goetz
NPI 1447741509
$3,428.45
in general payments reported to CMS, 2019-2025
43 companies · $2,161 in 2025
The $2,161 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $79.74 · 2023: $150 · 2024: $1,037 · 2025: $2,161.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,349.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,348.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $380.42 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $330.66 | 2024-2025 | |
| Janssen Biotech, INC. | $325.69 | 2022-2025 | Rybrevant, Erleada, Darzalex |
| Incyte Corporation | $183.49 | 2024-2025 | Jakafi, Monjuvi, Zynyz |
| Astrazeneca Pharmaceuticals LP | $176.72 | 2023-2025 | Enhertu, Lynparza |
| Abbvie INC. | $158.89 | 2024-2025 | |
| Celgene Corporation | $150.34 | 2022-2025 | Reblozyl, Pomalyst, Pomalyst |
| Merck Sharp & Dohme LLC | $137.53 | 2024-2025 | Keytruda, Welireg, Reblozyl |
| Pfizer INC. | $124.92 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $113.00 | 2024-2025 | Ninlaro, Iclusig, Alunbrig |
| Glaxosmithkline, LLC. | $101.51 | 2025 | Zejula, Jemperli |
| Aveo Pharmaceuticals, INC. | $78.00 | 2025 | |
| Tersera Therapeutics LLC | $74.09 | 2023-2024 | Zoladex |
| Daiichi Sankyo INC. | $72.19 | 2024-2025 | Enhertu |
| Genzyme Corporation | $71.32 | 2025 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Franziska Goetz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.